학술논문
MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs’ patients
Document Type
Article
Author
Catalano, Gianfranco; Zaza, Alessandra; Banella, Cristina; Pelosi, Elvira; Castelli, Germana; de Marinis, Elisabetta; Smigliani, Ariela; Travaglini, Serena; Ottone, Tiziana; Divona, Mariadomenica; Del Principe, Maria Ilaria; Buccisano, Francesco; Maurillo, Luca; Ammatuna, Emanuele; Testa, Ugo; Nervi, Clara; Venditti, Adriano; Voso, Maria Teresa; Noguera, Nelida Ines
Source
Leukemia; August 2023, Vol. 37 Issue: 8 p1600-1610, 11p
Subject
Language
ISSN
08876924; 14765551
Abstract
We characterize the metabolic background in distinct Acute Myeloid Leukemias (AMLs), by comparing the metabolism of primary AML blasts isolated at diagnosis with that of normal hematopoietic maturing progenitors, using the Seahorse XF Agilent. Leukemic cells feature lower spare respiratory (SRC) and glycolytic capacities as compared to hematopoietic precursors (i.e. day 7, promyelocytes). According with Proton Leak (PL) values, AML blasts can be grouped in two well defined populations. The AML group with blasts presenting high PL or high basal OXPHOS plus high SRC levels had shorter overall survival time and significantly overexpressed myeloid cell leukemia 1 (MCL1) protein. We demonstrate that MCL1 directly binds to Hexokinase 2 (HK2) on the outer mitochondrial membrane (OMM). Overall, these results suggest that high PL and high SRC plus high basal OXPHOS levels at disease onset, arguably with the concourse of MCL1/HK2 action, are significantly linked with shorter overall survival time in AML. Our data describe a new function for MCL1 protein in AMLs’ cells: by forming a complex with HK2, MCL1 co-localizes to VDAC on the OMM, thus inducing glycolysis and OXPHOS, ultimately conferring metabolic plasticity and promoting resistance to therapy.